Drug Type Monoclonal antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism CD40 inhibitors(Tumor necrosis factor receptor superfamily member 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Preclinical | South Korea | 14 Aug 2023 | |
Pemphigus | Preclinical | South Korea | 14 Aug 2023 |